Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.
Authors
van Zyl, Gert Uvesvan Mens, Thijs E
McIlleron, Helen
Zeier, Michele
Nachega, Jean B
Decloedt, Eric
Malavazzi, Carolina
Smith, Peter
Huang, Yong
van der Merwe, Lize
Gandhi, Monica
Maartens, Gary
Affiliation
Division of Medical Virology, Department of Pathology, NHLS Tygerberg and Stellenbosch University, Tygerberg, South Africa. guvz@sun.ac.zaIssue Date
2011-04
Metadata
Show full item recordAbstract
In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic failure.PubMed ID
21239995Language
enISSN
1944-7884ae974a485f413a2113503eed53cd6c53
10.1097/QAI.0b013e31820dc0cc
Scopus Count
Collections
Related articles
- Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
- Authors: La Rosa AM, Harrison LJ, Taiwo B, Wallis CL, Zheng L, Kim P, Kumarasamy N, Hosseinipour MC, Jarocki B, Mellors JW, Collier AC, ACTG A5273 Study Group.
- Issue date: 2016 Jun
- Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy.
- Authors: Court R, Gordon M, Cohen K, Stewart A, Gosnell B, Wiesner L, Maartens G
- Issue date: 2016 Aug
- Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
- Authors: Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team.
- Issue date: 2002 Jun 27
- Lopinavir/ritonavir: a review of its use in the management of HIV infection.
- Authors: Cvetkovic RS, Goa KL
- Issue date: 2003
- It is time to consider third-line options in antiretroviral-experienced paediatric patients?
- Authors: Zyl GU, Rabie H, Nuttall JJ, Cotton MF
- Issue date: 2011 Nov 15